Hodgkin's disease in 63 intravenous drug users infected with human immunodeficiency virus

S. Monfardini, U. Tirelli, E. Vaccher, R. Foa, F. Gavosto

Research output: Contribution to journalArticlepeer-review


Sixty-three cases of Hodgkin's disease in intravenous drug users (IVDUs) have been collected by the Italian Cooperative Group on AIDS-Related Tumors (GICAT). In most patients (74%) the histological pattern was that of mixed cellularity and lymphocyte depletion. In 39% of patients the initial symptom was a persistent lymph node enlargement due to persistent generalized lymphadenopathy (PGL). Unusual presentations included Waldeyer's ring, skin, meninges, colon, and pleura. After MOPP alternated or followed by ABVD, MOPP alone, or ABVD alone, 15 of 32 patients (47%) had a complete remission (CR) and 15 of 32 (47%) had a partial remission (PR). The median duration of CR was 14 months, while the median survival of patients with CR has not been reached; the median survival of patients treated with chemotherapy who had CD4 levels at presentation ≥ 400/mm 3 was significantly superior to that of those who had CD4 <400/mm 3. The overall median survival was only 14 months. Forty-four percent of patients receiving chemotherapy, with or without radiotherapy, developed opportunistic as well as nonopportunistic infections. Lethal hepatic toxicity was observed in one patient. Among IVDUs, unusual presentations of Hodgkin's disease occurred at a lower rate than was previously reported for homosexuals. Complete remissions could be achieved in almost half the patients, but non opportunistic infections, in addition to parenchymal function impairment due to drug abuse, may limit treatment administration in IVDUs.

Original languageEnglish
Pages (from-to)201-205
Number of pages5
JournalAnnals of Oncology
Issue numberSUPPL. 2
Publication statusPublished - 1991

ASJC Scopus subject areas

  • Cancer Research
  • Oncology


Dive into the research topics of 'Hodgkin's disease in 63 intravenous drug users infected with human immunodeficiency virus'. Together they form a unique fingerprint.

Cite this